Recently, the use of RAF inhibitors such as vemurafenib or sorafenib has been shown to paradoxically activate MAPK pathway in BRAF-wild type lung cancer or melanoma, due to induction of RAF (BRAF or CRAF) dimerization2, 4, 32. This evidence concerns the gene RAF1 and lung cancer.